dipyridamole

Summary

Summary: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)

Top Publications

  1. Vasu S, Bandettini W, Hsu L, Kellman P, Leung S, Mancini C, et al. Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013;15:85 pubmed publisher
    Regadenoson, dipyridamole and adenosine are commonly used vasodilators in myocardial perfusion imaging for the detection of obstructive coronary artery disease...
  2. Sloka S, Metz L, Hader W, Starreveld Y, Yong V. Reduction of microglial activity in a model of multiple sclerosis by dipyridamole. J Neuroinflammation. 2013;10:89 pubmed publisher
    ..On the basis of the reported inhibitory effects of dipyridamole on phosphodiesterase activity that result in the production of various anti-inflammatory outcomes, we selected ..
  3. Cognet T, Vervueren P, Dercle L, Bastie D, Richaud R, Berry M, et al. New concept of myocardial longitudinal strain reserve assessed by a dipyridamole infusion using 2D-strain echocardiography: the impact of diabetes and age, and the prognostic value. Cardiovasc Diabetol. 2013;12:84 pubmed publisher
    Although dipyridamole is a widely used pharmacological stress agent, the direct effects on myocardium are not entirely known. Diabetic cardiomyopathy can be investigated by 2D-strain echocardiography...
  4. Cortigiani L, Rigo F, Gherardi S, Bovenzi F, Molinaro S, Picano E, et al. Coronary flow reserve during dipyridamole stress echocardiography predicts mortality. JACC Cardiovasc Imaging. 2012;5:1079-85 pubmed publisher
    ..The goal of this study was to evaluate the ability of coronary flow reserve (CFR) over regional wall motion to predict mortality in patients with known or suspected coronary artery disease (CAD)...
  5. Karaguzel E, Kutlu O, Yulug E, Mungan S, Kazaz I, Tok D, et al. Comparison of the protective effect of dipyridamole and acetylsalicylic acid on long-term histologic damage in a rat model of testicular ischemia-reperfusion injury. J Pediatr Surg. 2012;47:1716-23 pubmed publisher
    ..We investigated the effects of dipyridamole and acetylsalicylic acid (ASA), 2 well-known platelet inhibitors, on testicular ischemia reperfusion injury.
  6. Bodi V, Husser O, Sanchis J, Nunez J, Monmeneu J, Lopez Lereu M, et al. Prognostic implications of dipyridamole cardiac MR imaging: a prospective multicenter registry. Radiology. 2012;262:91-100 pubmed publisher
    To evaluate dipyridamole cardiac magnetic resonance (MR) imaging in the prediction of major events (MEs) in patients with ischemic chest pain in a large multicenter registry...
  7. Greenhalgh J, Bagust A, Boland A, Martín Saborido C, Oyee J, Blundell M, et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess. 2011;15:1-178 pubmed publisher
    ..To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of ..
  8. Goudarzi B, Fukushima K, Bravo P, Merrill J, Bengel F. Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET. Eur J Nucl Med Mol Imaging. 2011;38:1908-16 pubmed publisher
    ..of distribution volume in individual patients or if it is generally comparable to the previous standard agents dipyridamole or adenosine, which are dosed based on weight...
  9. Bombardini T, Gherardi S, Arpesella G, Maccherini M, Serra W, Magnani G, et al. Favorable short-term outcome of transplanted hearts selected from marginal donors by pharmacological stress echocardiography. J Am Soc Echocardiogr. 2011;24:353-62 pubmed publisher
    ..The aim of this study was to establish the feasibility of an approach based on pharmacologic stress echocardiography as a gatekeeper for extended heart donor criteria...

More Information

Publications32

  1. Garcia Bonilla L, Sosti V, Campos M, Penalba A, Boada C, Sumalla M, et al. Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemia. Brain Res. 2011;1373:211-20 pubmed publisher
    b>Dipyridamole (DP) is a platelet inhibitor with known antithrombotic benefits in stroke prevention...
  2. Jensen B, Kleppe R, Kopperud R, Nygaard G, Døskeland S, Holmsen H, et al. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change. Platelets. 2011;22:8-19 pubmed publisher
    ..and therapeutic intervention of this pathway is clinically relevant for secondary prevention of stroke with dipyridamole. In the present study, we investigated whether dipyridamole affected the shape change of aspirinated platelets...
  3. d Esterre C, Lee T. Effect of dipyridamole during acute stroke: exploring antithrombosis and neuroprotective benefits. Ann N Y Acad Sci. 2010;1207:71-5 pubmed publisher
    ..A common secondary stroke prevention therapeutic, dipyridamole, has shown promise for reducing stroke recurrence without increasing bleeding...
  4. Guo S, Stins M, Ning M, Lo E. Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. Cerebrovasc Dis. 2010;30:290-6 pubmed publisher
    Increasing evidence suggests that beyond its antiplatelet properties, dipyridamole may have pleiotropic effects on other cells within the neurovascular elements of the brain...
  5. Franchi D, Cini D, Arpesella G, Gherardi S, Calamai I, Barletta G, et al. Second-opinion stress tele-echocardiography for the Adonhers (Aged donor heart rescue by stress echo) project. Cardiovasc Ultrasound. 2010;8:20 pubmed publisher
    ..In the simulation protocol, 30 dipyridamole stress echocardiograms were sent from the five peripheral echo labs to the central core lab in Pisa...
  6. Passer B, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, et al. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res. 2010;70:3890-5 pubmed publisher
    ..Two of these compounds, dipyridamole and dilazep, interfered with nucleotide metabolism by potently and directly inhibiting the equilibrative ..
  7. Venkatesh P, Pattillo C, Branch B, Hood J, Thoma S, Illum S, et al. Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway. Cardiovasc Res. 2010;85:661-70 pubmed publisher
    Anti-platelet agents, such as dipyridamole, have several clinical benefits for peripheral artery disease with the speculation of angiogenic potential that could preserve ischaemic tissue viability, yet the effect of dipyridamole on ..
  8. Dengler R, Diener H, Schwartz A, Grond M, Schumacher H, Machnig T, et al. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9:159-66 pubmed publisher
    ..The EARLY trial aimed to compare outcome in patients given aspirin plus extended-release dipyridamole twice daily either within 24 h of stroke or TIA or after 7 days of aspirin monotherapy...
  9. Leone O, Gherardi S, Targa L, Pasanisi E, Mikus P, Tanganelli P, et al. Stress echocardiography as a gatekeeper to donation in aged marginal donor hearts: anatomic and pathologic correlations of abnormal stress echocardiography results. J Heart Lung Transplant. 2009;28:1141-9 pubmed publisher
    ..donors underwent bedside echocardiography, with baseline and (when resting echocardiography was normal) dipyridamole (0.84 mg/kg in 6 min) or dobutamine (up to 40 microg/kg/min) stress echo...
  10. Sprigg N, Gray L, England T, Willmot M, Zhao L, Sare G, et al. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. PLoS ONE. 2008;3:e2852 pubmed publisher
    Aspirin, dipyridamole and clopidogrel are effective in secondary vascular prevention. Combination therapy with three antiplatelet agents might maximise the benefit of antiplatelet treatment in the secondary prevention of ischaemic stroke...
  11. Verro P, Gorelick P, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke. 2008;39:1358-63 pubmed publisher
    This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and ..